MET and neoplasm: These results were replicated in mice with tumors harboring MET aberrant signaling, as well as in mice with wild-type MET, reinforcing the potential efficacy of a combination strategy of immunotherapy and anti-MET inhibitors, regardless of the tumor MET status.